Pegylated IFN-α_2b plus ribavirin for treatment-naive patients coinfected with HCV and HIV

References

• Vogel M, Rockstroh J. Highlights of the third international workshop on HIV and hepatitis coinfection. Expert Rev. Anti Infect. Ther.5(5), 769–771 (2007).
   PubMedGoogle Scholar
• Saiz de la Hoya P, Bedia M, Murcia J, Cebria J, Sanchez-Paya J, Portilla J. [Predictive markers of HIV and HCV infection and co-infection among inmates in a Spanish prison]. Enferm. Infecc. Microbiol. Clin.23(2), 53–57 (2005).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol.44(1 Suppl.), S6–S9 (2006).
   PubMed Web of Science ®Google Scholar
• Laguno M, Sanchez-Tapias JM, Murillas J et al. [Advances in the diagnosis and treatment of hepatitis C virus infection in patients with and without HIV infection]. Enferm. Infecc. Microbiol. Clin.23(1), 32–40 (2005).
   PubMed Web of Science ®Google Scholar
• Koziel MJ. Influence of HIV co-infection on hepatitis C immunopathogenesis. J. Hepatol.44(1 Suppl.), S14–S18 (2006).
   PubMed Web of Science ®Google Scholar
• Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J. Hepatol.42(5), 615–624 (2005).
   PubMed Web of Science ®Google Scholar
• Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J. Hepatol.44(1 Suppl.), S28–34 (2006).
   PubMed Web of Science ®Google Scholar
• Martin-Carbonero L, Soriano V, Valencia E, Garcia-Samaniego J, Lopez M, Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res. Hum. Retroviruses17(16), 1467–1471 (2001).
   PubMed Web of Science ®Google Scholar
• Moreno A, Barcena R, Garcia-Garzon S et al. Viral kinetics and early prediction of nonresponse to peg-IFN-α2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus. J. Viral Hepat.13(7), 466–473 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno A, Barcena R, Garcia-Garzon S et al. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α2b/ribavirin. J. Hepatol.43(5), 783–790 (2005).
   PubMed Web of Science ®Google Scholar
• Ahn J, Flamm S. Peginterferon-α2b and ribavirin. Expert Rev. Anti Infect. Ther.2(1), 17–25 (2004).
   PubMedGoogle Scholar
• Crespo M, Sauleda S, Esteban JI et al. Peginterferon α2b plus ribavirin vs interferon α2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J. Viral Hepat.14(4), 228–238 (2006).
   Web of Science ®Google Scholar
• EASL international consensus conference on hepatitis C. Paris, 26–28, February 1999, consensus statement. European Association for the Study of the Liver. J. Hepatol.30(5), 956–961 (1999).
   PubMedGoogle Scholar
• Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon α2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol.40(6), 993–999 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Murillas J, Blanco JL et al. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS18(13), F27–F36 (2004).
   Google Scholar
• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α2b plus ribavirin compared with interferon α2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358(9286), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Mauss S. Treatment of viral hepatitis in HIV-coinfected patients-adverse events and their management. J. Hepatol.44(1 Suppl.), S114–S118 (2006).
   Google Scholar
• Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. J. Hepatol.44(1 Suppl.), S40–S43 (2006).
   PubMed Web of Science ®Google Scholar
• PegIntron®, package insert. Schering-Plough Corporation. NJ, USA, June (2007).
   Google Scholar
• Rebetol®, package insert. Schering-Plough Corporation. NJ, USA, July (2007).
   Google Scholar
• Grace MJ, Cutler DL, Bordens RW. Pegylated IFNs for chronic hepatitis C: an update. Expert Opin. Drug Deliv.2(2), 219–226 (2005).
   PubMedGoogle Scholar
• Grace MJ, Cutler D. Pegylating IFNs at His-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir. Chem. Chemother.15(6), 287–297 (2004).
   PubMedGoogle Scholar
• Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J. Hepatol.31(Suppl. 1), 152–159 (1999).
   PubMed Web of Science ®Google Scholar
• Grace MJ, Lee S, Bradshaw S et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-α antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. Chem.280(8), 6327–6336 (2005).
   PubMed Web of Science ®Google Scholar
• Caliceti P. Pharmacokinetics of pegylated interferons: what is misleading? Dig. Liver Dis.36(Suppl. 3), S334–S339 (2004).
   Google Scholar
• Glue P, Fang JW, Rouzier-Panis R et al. Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther.68(5), 556–567 (2000).
   PubMed Web of Science ®Google Scholar
• Grace MJ, Bordens RW, Cutler DL. Peginterferons for the treatment of chronic hepatitis C. Hepatology Rev.2, 3–9 (2005).
   Google Scholar
• Jen JF, Glue P, Ezzet F et al. Population pharmacokinetic analysis of pegylated interferon α2b and interferon α2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther.69(6), 407–421 (2001).
   PubMed Web of Science ®Google Scholar
• Lurie Y, Rouzier-Panis R, Webster GJ et al. Optimal dosing frequency of pegylated interferon α2b monotherapy for chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol.3(6), 610–615 (2005).
   PubMed Web of Science ®Google Scholar
• Glue P. The clinical pharmacology of ribavirin. Semin. Liver Dis.19(Suppl. 1), 17–24 (1999).
   PubMed Web of Science ®Google Scholar
• Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am. J. Kidney Dis.43(1), 140–146 (2004).
   PubMed Web of Science ®Google Scholar
• Glue P, Rouzier-Panis R, Raffanel C et al. A dose-ranging study of pegylated interferon α2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology32(3), 647–653 (2000).
   PubMed Web of Science ®Google Scholar
• Carrat F, Bani-Sadr F, Pol S et al. Pegylated interferon α2b vs standard interferon α2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA292(23), 2839–2848 (2004).
   PubMed Web of Science ®Google Scholar
• Fried MW. Viral factors affecting the outcome of therapy for chronic hepatitis C. Rev. Gastroenterol. Disord.4(Suppl. 1), S8–S13 (2004).
   Google Scholar
• Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J. Hepatol.44(1 Suppl.), S44–S48 (2006).
   PubMed Web of Science ®Google Scholar
• Wu L, Kottilil S, Lempicki R et al. Hepatic histologic response (HR) to combination therapy among HCV/HIV-coinfected individuals: interferon induces HR independent of sustained virologic response (SVR). AIDS Res. Hum. Retroviruses22(11), 1091–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology128(3), 636–641 (2005).
   PubMed Web of Science ®Google Scholar
• Duong M, Petit JM, Piroth L et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J. Acquir. Immune Defic. Syndr.27(3), 245–250 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Brown RS Jr, McCone J et al. Impact of weight-based ribavirin with peginterferon α2b in African Americans with hepatitis C virus genotype 1. Hepatology46(4), 982–990 (2007).
   PubMed Web of Science ®Google Scholar
• Smith J, Han SH. ‘True’ weight-based dosing versus ‘flat’ dosing of ribavirin: will the WIN-R please come forward? Hepatology46(4), 953–956 (2007).
   PubMed Web of Science ®Google Scholar
• Teo M, Hayes P. Management of hepatitis C. Br. Med. Bull.70, 51–69 (2004).
   PubMed Web of Science ®Google Scholar
• Perez-Olmeda M, Nunez M, Romero M et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS17(7), 1023–1028 (2003).
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Treatment algorithm for the management of hepatitis C in HIV-coinfected persons. J. Hepatol.44(1 Suppl.), S49–S55 (2006).
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Denoeud L, Morand P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J. Acquir. Immune Defic. Syndr.45, 123–125 (2007).
   PubMed Web of Science ®Google Scholar
• Voigt E, Schulz C, Klausen G et al. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. J. Infect.53(1), 36–42 (2006).
   PubMed Web of Science ®Google Scholar
• Cargnel A, Angeli E, Mainini A et al. Open, randomized, multicentre italian trial on PEG-IFN-plus ribavirin versus PEG-IFN-monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Antivir. Ther.10(2), 309–317 (2005).
   PubMed Web of Science ®Google Scholar
• Santin M, Shaw E, Garcia MJ et al. Efficacy and safety of pegylated interferon-α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS Res. Hum. Retroviruses22(4), 315–320 (2006).
   PubMed Web of Science ®Google Scholar
• Moreno L, Quereda C, Moreno A et al. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS18(1), 67–73 (2004).
   PubMed Web of Science ®Google Scholar
• Ballesteros AL, Franco S, Fuster D et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS18(1), 59–66 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Cifuentes C, Murillas J et al. A randomized trial to compare the efficacy and safety of Peg interferon α2b plus ribavirin versus Peg interferon α2a plus ribavirin for treatment of chronic hepatitis C in coinfected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA 3–8 February 2008.
   Google Scholar
• Deutsch M, Hadziyannis SJ. Old and emerging therapies in chronic hepatitis C: an update. J. Viral Hepat.15(1), 2–11 (2008).
   PubMed Web of Science ®Google Scholar